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Abstract
Recently, the neuropeptide S (NPS) neurotransmitter system has been identiﬁed as a promising psycho-
pharmacological drug target given that NPS has shown anxiolytic-like and stress-reducing properties and
memory-enhancing eﬀects in rodent models. NPS binds to the G-protein-coupled receptor encoded by the
neuropeptide S receptor gene (NPSR1). A functional variant within this gene leads to an amino-acid
exchange (rs324981, Asn107Ile) resulting in a gain-of-function in the Ile107 variant which was recently
associated with panic disorder in two independent studies. A potential psychopharmacological eﬀect
of NPS on schizophrenia psychopathology was demonstrated by showing that NPS can block NMDA
antagonist-induced deﬁcits in prepulse inhibition. We therefore explored a potential role of the NPSR1
Asn107Ile variation in schizophrenia. A case-control sample of 778 schizophrenia patients and 713 healthy
control subjects was successfully genotyped for NPSR1Asn107Ile. Verbal declarative memory and acoustic
startle response were measured in subsamples of the schizophrenia patients. The case-control comparison
revealed that the low-functioning NPSR1 Asn107 variant was signiﬁcantly associated with schizophrenia
(OR 1.19, p=0.017). Moreover, speciﬁcally decreased verbal memory consolidation was found in homo-
zygous Asn107 carriers while memory acquisition was unaﬀected by NPSR1 genotype. The schizophrenia
patients carrying the Ile107 variant demonstrated signiﬁcantly reduced startle amplitudes but unaﬀected
prepulse inhibition and habituation. The present study conﬁrms ﬁndings from rodent models demon-
strating an eﬀect of NPS on memory consolidation and startle response in schizophrenia patients. Based
on these ﬁndings, we consider NPS as a promising target for antipsychotic drug development.
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Introduction
Schizophrenia is a neuropsychiatric disorder with
abnormalities in various neurotransmitter systems
and important contributions of genetic factors in its
pathogenesis. From the eﬃcacy of ﬁrst-generation anti-
psychotics due to dopamine D2 receptor antagonism a
major role of dopamine in the pathogenesis of schizo-
phrenia was derived (Carlsson, 1978 ; Howes & Kapur,
2009). The development of atypical antipsychotics
with lower D2 receptor aﬃnity such as clozapine
demonstrating comparable eﬀects of symptomatic re-
lief in schizophrenia pointed to an additional in-
volvement of other neurotransmitter systems (Arnt &
Skarsfeldt, 1998). Translating this fundamental ﬁnding
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to the ﬁeld of pharmacogenetic research gave rise to
the discovery of several promising candidate genes
related to other transmitter systems (reviewed in
Arranz & de Leon, 2007). In return, replicable schizo-
phrenia candidate genes modulating neurotransmis-
sion may also help to identify promising targets for
future antipsychotic drug development.
Recently, neuropeptide S (NPS) has been described
which binds to a G-protein-coupled receptor, the
neuropeptide S receptor (NPSR) (Reinscheid & Xu,
2005b ; Xu et al. 2004). In rats, NPSR mRNA is strongly
expressed in several discrete nuclei or regions within
the CNS including the amygdala, hypothalamus,
motor cortex 2, and retrosplenial agranular cortex
(Xu et al. 2004). Lower expression was found in the
hippocampus and somatosensory cortex. Activation of
NPSR leads to an increase of intracellular Ca2+ and
cAMP thus indicating an excitatory eﬀect of NPS
(Reinscheid & Xu, 2005a). In contrast to NPSR which is
distributed across several brain regions, precursors of
NPS are only expressed in some brainstem areas in-
cluding a novel locus between the noradrenergic locus
coeruleus and Barrington’s nucleus (Xu et al. 2004).
Central administration of NPS has been shown to
increase locomotor activation and to suppress sleep
in rodents (Reinscheid, 2008). Moreover, mice show
more exploratory behaviour in diﬀerent standardized
behavioural tests after injections of NPS thus suggest-
ing a strong anxiolytic-like eﬀect (Leonard et al.
2008; Rizzi et al. 2008; Xu et al. 2004). Recently, Fendt
et al. (2010) also demonstrated the anxiety-reducing
eﬀect of NPS injections into the amygdala on the
acoustic startle response. In their experiment, mice
injected with 1 nmol NPS did not show the typically
observed potentiation of fear when an additional
shock was administered during the acoustic startle
trials.
One mechanism by which NPS induces the replic-
able anxiolytic eﬀect may be that it alters memory-
related processes. Injections of NPS in the amygdala
led to accelerated extinction of conditioned fear in
mice while NPS treatment before fear conditioning
did not show any eﬀect on anxiety-related memory
(Ju¨ngling et al. 2008). Okamura et al. (2010a) extended
these ﬁndings in a series of experiments yielding a
speciﬁc improvement of memory consolidation with
unaﬀected acquisition due to NPS injections. Of note,
the authors also demonstrated this consolidation-
promoting eﬀect of NPS in a non-aﬀective memory
task (object recognition). Thus, it was suggested that
NPS stimulates neuronal plasticity with a general en-
hancing eﬀect on memory consolidation irrespective
of content. In sum, NPS demonstrates anxiolytic-like
and stress-reducing eﬀects and appears to enhance
memory consolidation in animals.
NPSR is encoded by a gene located on chromosome
7p14 comprising at least nine exons (NPSR1). An Asn
to Ile exchange at position 107 (Asn107Ile, rs324981) has
been identiﬁed with increased agonist potency in the
Ile107 variant (Reinscheid, 2008). Thus, Ile107 encoded
by the T-allele demonstrates a 10-fold higher NPS
transmission compared to the Asn encoding A-allele
(Bernier et al. 2006; Reinscheid et al. 2005b). The AA
genotype of this coding variant was found to be
under-represented inmale patients with panic disorder
while no association with schizophrenia or attention
deﬁcit hyperactivity disorder emerged (Okamura et al.
2007). This association with panic disorder was re-
cently replicated in two independent samples by
Domschke et al. (2010), who, in contrast to Okamura
et al. (2007) found a stronger association in female
patients. Moreover, in the Domschke et al. study, panic
patients carrying the disease-related Ile107 variant
showed more self-reported anxiety and higher in-
creases in heart rate during behavioural testing.
Combining genotype and imaging data yielded
that carriers of the Ile107 variant signiﬁcantly failed
to recruit the dorsolateral prefrontal cortex (DLPFC),
orbitofrontal cortex (OFC) and anterior cingulate
cortex (ACC) during the perception of fearful faces
(Domschke et al. 2010).
Recently, NPS was discussed as a potential phar-
macological drug target for schizophrenia (Okamura
et al. 2010b). These authors investigated sensorimotor
gating of the acoustic startle response in mice.
Injections of MK-801, an NMDA antagonist, served as
a pharmacological model of schizophrenia typically
leading to disrupted prepulse inhibition (PPI).
Additional injections of NPS signiﬁcantly attenuated
this eﬀect as indicated by recovered PPI while the
startle amplitude was not changed. Thus, by showing
that NPS blocks MK-810 NMDA antagonism, this
study suggests a potential antipsychotic eﬀect of NPS
(Okamura et al. 2010b). Deﬁcient PPI is a highly re-
plicable feature of schizophrenia across studies with
some studies also reporting impaired acoustic startle
reﬂexes (Braﬀ et al. 2001; Hammer et al. 2011; Meincke
et al. 2004; Moriwaki et al. 2009; Quednow et al. 2006b,
2008). We therefore aimed to explore whether the
NPSR1 genotype would aﬀect sensorimotor gating
and startle reﬂexes in patients suﬀering from schizo-
phrenia.
The purpose of the present study was 2-fold : we
sought (1) to examine the potential association of
NPSR1 genotype with schizophrenia in a large case-
control sample and (2) to elucidate the functional
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characteristics of the NPSR1 Asn107Ile variation on
neurocognition in schizophrenia. Based on the ﬁnd-
ings of Okamura et al. (2007, 2010b) we therefore
analysed sensorimotor gating applying an acoustic
startle paradigm and verbal declarative memory. It
was hypothesized that the NPSR1 genotype would
aﬀect the acoustic startle amplitude, PPI, and memory
consolidation but not memory acquisition.
Experimental procedures
Sample
Schizophrenia patients (n=778) were recruited from
the Departments of Psychiatry of the Universities of
Bonn, Du¨sseldorf, Cologne, and from the Central
Institute of Mental Health of Mannheim, Germany.
Diagnoses were established according to the criteria of
ICD-10 (WHO, 1992) and DSM-IV (APA, 1994) by ex-
perienced psychiatrists or clinical psychologists.
Healthy control subjects (n=713) were recruited from
community registers or via local advertisement and
were screened for the absence of any psychiatric dis-
order. The study was approved by the appropriate
ethics committees and all subjects gave written in-
formed consent prior to inclusion. Mean age of schizo-
phrenia patients was 34.1 yr (S.D.=10.6 yr) while
healthy control subjects were 39.3 yr (S.D.=13.5 yr) on
average. Four hundred and sixty (59.1%) schizo-
phrenia patients and 338 (48.3%) healthy controls
were male.
Verbal declarative memory was tested in a subset of
199 schizophrenia patients and 204 control subjects
allowing us to explore the functional consequences of
NPSR1 genotype. In the neuropsychologically charac-
terized sample, neither age, sex distribution, and pre-
morbid education as assessed with the MWT-B in the
schizophrenia patients and the healthy control sub-
jects, nor age at onset and duration of illness in the
schizophrenia patients were related to NPSR1 geno-
type (all p>0.179). In the healthy volunteers, recog-
nition data were only available for 175 subjects.
Acoustic startle response was measured in a second
subset of 71 schizophrenia patients of which 26
were included in the neuropsychological sample. All
of these subjects were inpatients admitted to the
Department of Psychiatry and Psychotherapy of the
University of Bonn and were considered eligible for
the study if the following criteria were met : a diag-
nosis of schizophrenia according to DSM-IV, age be-
tween 18 and 65 years, and central European ancestry.
Patients were excluded if they had a history of
a neurological disease, substance dependency, or a
severe somatic disease. In this subset, every patient
was evaluated by a Structured Clinical Interview
(SCID-I) according to DSM-IV and clinical symptoms
were measured with the Positive and Negative
Syndrome Scale (PANSS; Kay et al. 1992). In this
sample, the NPSR1 genotype was also unrelated to
age, sex, education, medication status and dose, and
PANSS symptom rating (all p>0.10).
Measures
Neuropsychological measures included the German
version of the Auditory Verbal Learning Test (AVLT,
Helmstaedter et al. 2001). The AVLT is a standardized
measure of verbal declarative memory asking the
subjects to learn and recall 15 items of a word list.
Selected outcome variables were (1) recall after the
ﬁrst trial, (2) total recall over trials 1–5, (3) recall after
interference (trial 6), (4) delayed recall after 30 min
(trial 7), and (5) recognition as indicated words cor-
rectly recognized [p(A) according to Geﬀen et al.
(1990)]. In addition, pre-morbid verbal education
was assessed with the Mehrfachwahl-Wortschatz-
Test (MWT-B), a German vocabulary test (Lehrl et al.
1999).
PPI was recorded and analysed as described in
our previous work (Quednow et al. 2006a, b, 2008).
Acoustic startle stimuli were presented binaurally
through headphones (TDH-39-P; Maico). Each session
began with a 4-min acclimation period of 70 dB back-
ground white noise that was continued throughout the
session. Participants received 73 sound pulses with a
power of 116 dB along with 70 dB background white
noise. In 36 of the trials, the pulse was preceded by an
86-dB prepulse with an inter-stimulus interval (ISI) of
120 ms. The eye-blink component of the acoustic
startle response (right eye) was measured using an
electromyographic startle system (San Diego Instru-
ments, USA). Recorded EMG activity was bandpass-
ﬁltered (1–1000 Hz). A 50-Hz notch ﬁlter was also
used to eliminate 50-Hz interference. The ampliﬁer
gain was kept constant for all participants, and the
EMG was recorded from the onset of the acoustic
startle stimulus for 250 ms with a sampling rate of
1 ms.
Voluntary and spontaneous blinks were excluded
from further analysis using the registration par-
ameters described by Braﬀ et al. (1992). The latency
to startle response onset was deﬁned by a shift of
2.28 mV (six digital units) from the baseline value oc-
curring 21–120 ms after the acoustic startle stimulus.
Latency-to-response peak was deﬁned as the point of
maximal amplitude that occurred within 150 ms after
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the startle stimulus. Response rejections were made
both in case of onset-to-peak latencies >95 ms and
baseline shifts>34.2 mV (>90 digital units). Two pa-
tients (2.8% of the total sample) with more than 50%
response rejections were excluded from data analysis.
All remaining subjects show a startle amplitude >25
units – the commonly used threshold for analysable
startle data (Braﬀ et al. 1992). Smoking ad libitum was
permitted before testing (Kumari & Gray, 1999).
Genotyping
DNA for single nucleotide polymorphism (SNP) gen-
otyping was isolated from EDTA anticoagulated blood
using the Qiagen protocol for Blood & Cell Culture
DNA Maxi kit (Qiagen, Germany). PCR was per-
formed using 12.5 ng DNA, the Taqman1 Universal
PCR MasterMix, No AmpErase1 UNG and the
Taqman1 SNP Genotyping Assays for each SNP
(all provided by Applied Biosystems, USA) according
to the protocol for Taqman1 SNP genotyping (Applied
Biosystems). Each assay consisted of the unlabelled
forward and reverse primers and the FAM and VIC
dye-labelled MGB probes. These assays are designed
for allelic discrimination of speciﬁc SNPs. Both alleles
were scored in a single well by measuring the ﬂuor-
escence at the end of PCR using a Tecan Ultra 384
reader (Tecan, Germany). Excitation- and emission-
wavelengths for the FAM-labelled probes were 485
and 535 nm and for the VIC-labelled probes 535 and
590 nm, respectively.
Statistics
Armitage trend test was employed to analyse case-
control data using the FamHap program (Becker &
Knapp, 2004). The mean %PPI of startle amplitude
was calculated using the formula :
% PPI=100r
amplitude on PA trialsxamplitude on PP trials
amplitude on PA trials
,
where PA=pulse-alone and PP=prepulse (Braﬀ et al.
1992). For the assessment of startle habituation, PA
trials were each divided into six blocks. The % ha-
bituation was calculated as the reduction in startle
magnitude between the ﬁrst and last block of PA and
PP trials :
% habituation=100r
first blockxlast block
first block
(Geyer & Braﬀ, 1982). As a further measure for
habituation, the linear gradient coeﬃcient b was
calculated across six blocks of PA and PP trials within
each subject
b= n
X
xyx
X
x
  X
y
  
= n
X
x2x
X
x
 
2
 
,
where x=block number, y=startle amplitude PA trial
per block, according to Geyer & Braﬀ (1982). Startle
reactivity was assessed by the mean amplitude of the
ﬁrst block of PA trials and the mean amplitude of all
PA trials. All data were analysed by analysis of vari-
ance (ANOVA) with exception of frequency data.
Frequency data were analysed using x2 tests. The
conﬁrmatory statistical comparisons were performed
with signiﬁcance level set at p<0.05 (two-tailed).
Results
First, we compared NPSR1 genotype distribution in
our large case-control sample comprising 778 schizo-
phrenia patients and 713 healthy control subjects. The
Asn107Ile polymorphism of the NPSR1 gene was in
Hardy–Weinberg equilibrium in the schizophrenia
patients and healthy control subjects (p=0.720 and
0.823, respectively). Homozygosity for the Asn107
variant was found in 31.2% of schizophrenia patients
and in 26.6% of healthy control subjects. Conversely,
homozygosity for the Ile107 variant was found in only
18.9% of schizophrenia patients and 23.0% of healthy
comparison subjects. Thus schizophrenia patients
were more likely to carry the low functioning Asn107
variant compared to the healthy control group
[Armitage trend test : x2(1)=5.711, p=0.01685; odds
ratio : Asn107=1.19, 95% CI 1.03–1.38]. Complete
genotype data of the case-control sample is given in
Table 1.
We analysed verbal declarative memory in the
schizophrenia patients and healthy control subjects
computing a series of 2r2 ANOVAs. Given that the
low-functioning Asn107 variant was signiﬁcantly re-
lated to schizophrenia in this study and based on
previous studies (Domschke et al. 2010; Okamura et al.
2007), we statistically compared homozygous Asn107
subjects (Asn/Asn) against carriers of the Ile107 variant
(Ile).
As expected, all ANOVAs showed marked memory
impairments in the schizophrenia patients compared
to the healthy control group (all p<0.001). Following
the AVLT test protocol, no signiﬁcant genotype eﬀects
or genotyperdiagnosis interactions were found for
the ﬁrst trial (genotype: F1,399=0.24, p=0.624; interac-
tion : F1,399=0.49, p=0.480) or with regard to total
learning over all ﬁve trials (genotype: F1,399=1.12,
p=0.290 ; interaction : F1,399=1.13, p=0.288). Analysing
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AVLT free recall after interference (trial 6) showed a
signiﬁcant main eﬀect for genotype with an insigniﬁ-
cant interaction (genotype: F1,399=4.49, p=0.035; inter-
action : F1,399=0.94, p=0.332) indicating impairments
in homozygous Asn107 carriers compared to Ile107 sub-
jects (Asn/Asn=10.3¡3.3, Ile=11.2¡3.2). The same
pattern was found for AVLT delayed recall (trial 7) :
subjects with the Asn/Asn genotype recalled fewer
words after 30 min compared to subjects with at least
one Ile107 allele (Asn/Asn=10.4¡3.5, Ile=11.3¡3.2 ;
genotype: F1,399=4.66, p=0.032; interaction : F1,399=
1.50, p=0.222). With regard to recognition, an insig-
niﬁcant main eﬀect for genotype and a genotyper
diagnosis interaction eﬀect on trend-level was found
(genotype: F1,370=1.43, p=0.233 ; interaction : F1,370=
2.95, p=0.087). Inspection of the means indicated a
speciﬁcally reduced recognition in Asn/Asn schizo-
phrenia patients compared to Ile107 patients while no
such eﬀect was evident in the healthy control subjects
(Table 2).
In a second step, we also analysed the eﬀects of the
NPSR genotype in the schizophrenia patients and
the healthy control group separately to further explore
which group contributed to the eﬀects reported above.
The schizophrenia patients with the Asn/Asn variant
and patients with an Ile107 variant showed comparable
memory acquisition during the ﬁrst trial and with
regard to total learning over all ﬁve trials (p>0.10).
However, when analysing free recall of the word list,
signiﬁcant genotype eﬀects emerged in schizophrenia
patients. Thus, patients homozygous for the Asn107
variant recalled fewer words after interference (F1,197=
3.99, p=0.047) and after delay (F1,197=4.64, p=0.032)
compared to patients with the Ile107 variant. This
genotype eﬀect was also found with regard to
recognition with a reduced probability of correct
Table 1. Association of the Asn107Ile polymorphism of the neuropeptide S
receptor (NPSR1) gene in a large schizophrenia case-control sample
Schizophrenia patients
(n=778)
Healthy controls
(n=713) OR (95% CI)
NPSR1 genotypea
Asn/Asn (AA) 243 (31.2%) 190 (26.6%) 1.25 (0.99–1.56)
Asn/Ile (AT) 388 (49.9%) 359 (50.4%) 0.98 (0.80–1.20)
Ile/Ile (TT) 147 (18.9%) 164 (23.0%) 0.78 (0.61–1.00)
NPSR1 allelesb
Asn (A allele) 874 (56.2%) 739 (51.8%) 1.19 (1.03–1.38)
Ile (T allele) 682 (43.8%) 687 (48.2%) 0.84 (0.73–0.97)
OR, Odds ratio ; CI, conﬁdence interval.
a x2 test on genotype distribution : p=0.057.
b Armitage trend test : global p=0.017.
Table 2. Verbal memory in schizophrenia patients and healthy controls stratiﬁed for Asn107Ile of the NPSR1 gene
Schizophrenia patients Healthy controls
Asn/Asn Asn/Ile Ile/Ile
Asn/Asn
vs. Ile Asn/Asn Asn/Ile Ile/Ile
Asn/Asn
vs. Ile
N 59 105 35 50 105 49
AVLT trial 1 6.3 (2.1) 6.6 (1.8) 6.8 (1.6) p=0.539 7.9 (2.4) 7.8 (2.2) 7.9 (1.9) p=0.934
AVLT trials 1–5 47.6 (11.7) 49.9 (10.6) 50.2 (12.3) p=0.169 57.7 (8.3) 57.5 (9.3) 58.1 (8.1) p=0.997
AVLT trial 6 9.0 (3.3) 10.0 (3.1) 10.0 (4.2) p=0.047 11.9 (2.5) 12.0 (2.7) 12.8 (2.3) p=0.361
AVLT trial 7 9.0 (3.6) 10.0 (3.1) 10.2 (3.9) p=0.032 12.1 (2.4) 12.3 (2.6) 12.8 (2.5) p=0.446
AVLT recognition
p(A)
0.74 (0.16) 0.80 (0.16) 0.78 (0.15) p=0.034 0.89 (0.13) 0.88 (0.15) 0.89 (0.15) p=0.716
AVLT, Rey auditory verbal learning test.
Data are expressed as mean with standard deviation (S.D.) in parentheses. Bold numbers indicate signiﬁcant ﬁndings.
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recognition [p(A)] in Asn/Asn carriers compared
to Ile107 subjects (F1,197=4.53, p=0.034). These results
suggest a speciﬁc eﬀect ofNPSR1 genotype onmemory
consolidation in schizophrenia with free recollection
and recognition being aﬀected while acquisition re-
mains intact (see Fig. 1 for illustration). In the healthy
control subjects, no eﬀect of NPSR1 genotype on
memory performance was found (p>0.20). Complete
verbal declarative memory data of schizophrenia
patients and healthy controls is given in Table 2.
In the schizophrenia subpopulation assessed with
the acoustic startle paradigm, the Asn107Ile poly-
morphism was distributed in accordance to Hardy–
Weinberg equilibrium and NPSR1 genotype groups
did not diﬀer regarding demographic and clinical data
(see Table 3).
The means (¡S.E.M.) of the acoustic startle paradigm
are given in Table 3. In contrast to our expectations
based on the study of Okamura et al. (2010b), PPI
was not signiﬁcantly modulated by the coding NPSR1
polymorphism Asn107Ile (p>0.20). However, both
startle reactivity measures (mean amplitude of PA
trials in the ﬁrst block as well as across all blocks) were
consistently aﬀected by genotype with carriers of
the Ile107 variant showing signiﬁcantly reduced startle
amplitudes compared to patients homozygous for
the Asn107 variant (ﬁrst block of PA trials : t67=2.7,
p=0.008 ; all PA trials : t67=3.2, p=0.003) (Fig. 2).
To investigate the impact of possible confounding
factors we also introduced age, gender, medication
status, smoking, and education as separate covariates
in ANCOVAs of the genotype eﬀect on startle
reactivity. The NPSR1 genotype eﬀect on both startle
reactivity measures remained signiﬁcant in every
analysis (at least p<0.05). Age was the only signiﬁcant
covariate (ﬁrst block of PA trials : p=0.004; all PA
trials : p=0.003) and correlation analysis showed that
startle reactivity decreases with age (both startle
parameters : r=x0.44, p<0.001).
Habituation parameters were not signiﬁcantly in-
ﬂuenced by NPSR1 rs324981 genotype (see Table 3).
Additionally, we compared schizophrenia patients
of the present study with 46 matched (according
to age, gender, and education) but non-genotyped
healthy control subjects, who were assessed with the
same PPI paradigm in our previous studies (Quednow
et al. 2006b, 2008). The total group of schizophrenia
patients displayed signiﬁcantly decreased PPI (mean¡
S.E.M. %PPI in controls : 56.9¡3.2, t113=3.1, p=0.002)
and diminished startle reactivity in the ﬁrst block of
PA trials but not across all PA trials (ﬁrst block of PA
trials in controls : 382¡45.1 arbitrary units, t113=2.6,
p=0.01 ; all PA trials in controls 241¡29.3 arbitrary
units, t113=1.3, p>0.20) compared to controls. To
examine the direction of the genotype eﬀect on startle
reactivity, we compared healthy controls with both
genotype groups (Asn/Asn vs. Asn/Ile+Ile/Ile) of
schizophrenia patients. Patients carrying the Ile107
variant showed signiﬁcantly reduced startle ampli-
tudes compared to healthy controls (ﬁrst block of PA
trials : t97=3.2, p=0.002; all PA trials : t97=2.1, p=0.04),
whereas patients homozygous for the Asn107 variant
did not diﬀer from the normal population (ﬁrst block
of PA trials : t60=0.2, p>0.80 ; all PA trials : t60=1.1,
p>0.25).
Discussion
The present study investigated the functional poly-
morphism Asn107Ile of the neuropeptide S receptor
gene (NPSR1) in schizophrenia. In a large case-control
sample, the schizophrenia patients were more likely to
carry the low-functioning Asn107 variant compared
to the healthy control group. Moreover, compared to
carriers of the Ile variant, subjects homozygous for the
Asn107 variant were signiﬁcantly impaired in verbal
memory functioning in a neuropsychologically charac-
terized subsample. This ﬁnding was also observed in
the sample of schizophrenia patients but was not seen
in healthy control subjects alone. While PPI was not
aﬀected byNPSR1 genotype, strongly decreased startle
reactivity was found in the schizophrenia patients
with the Ile107 variant.
According to a study conducted by Reinscheid et al.
(2005b), the Ile107 variant encoded by the T-allele
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Fig. 1. Speciﬁcally impaired memory consolidation in
schizophrenia patients homozygous for the NPSR1 Asn107
variant. Ile, Carriers of the Ile variant (Asn/Ile or Ile/Ile).
Mean words retrieved are given with standard error of the
mean (S.E.M.). Trials 1–5 are acquisition trials, trials 6 and 7
are free recall trials after an interference list and after delay.
* p<0.05.
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Table 3. Demographic data and psycho-physiological parameters of 69 schizophrenia patients grouped according to their NPSR1 Asn107Ile genotype
NPSR1 Asn107Ile variant Asn/Asn Asn/Ile Ile/Ile Total F/x2 df/dferr p g
2
p
Na 16 (23.2%) 40 (58%) 13 (18.8%) 69 (100%) 1.43 1 0.23 –
Age (yr) 31.9 (2.4) 35.8 (1.7) 34.8 (3.5) 34.7 (1.3) 0.73 2/66 0.49 0.02
Years of education 14.7 (0.8) 14.0 (0.5) 15.9 (0.5) 14.5 (0.4) 1.82 2/66 0.17 0.06
Men (%) 75.0% 67.5% 69.2% 69.6% 0.30 2 0.86 –
Current smokers (%) 50.0% 55.0% 53.8% 53.6% 0.11 2 0.94 –
Medication status (%) (unmedicated/typical/
atypical antipsychotic)
31.3/25.0/43.8% 15.0/15.0/70% 23.1/15.4/61.5% 20.3/17.4/62.3% 3.51 4 0.48 –
Daily chlorpromazine equivalentsb 203 (58.2) 297 (33.3) 221 (53.2) 261 (25.9) 1.41 2/66 0.25 0.05
PANSS positivec 17.1 (1.9) 19.3 (1.2) 16.4 (2.5) 18.2 (0.9) 0.52 1/68 0.47 0.01
PANSS negativec 19.8 (1.6) 20.8 (1.2) 20.5 (2.4) 20.5 (0.9) 0.19 1/68 0.66 0.00
PANSS generalc 39.1 (3.1) 41.2 (2.3) 36.9 (3.8) 40.0 (1.7) 0.09 1/68 0.77 0.02
PANSS totalc 76.0 (5.9) 82.2 (4.2) 73.8 (7.9) 79.3 (3.1) 0.35 1/68 0.56 0.01
First block, mean amplitude of
pulse-alone trials (arbitrary units)c
363 (50.5) 241 (27.1) 201 (43.6) 262 (22.1) 6.96 1/68 0.01 0.09
Mean amplitude of all pulse-alone
trials (arbitrary units)c
304 (41.7) 176 (24.8) 141 (34.2) 199 (19.6) 9.79 1/68 0.003 0.13
Mean percent prepulse inhibition
(SOA 120 ms)c
40.7% (6.8) 44.4% (4.4) 35.6% (7.8) 41.9% (3.3) 0.04 1/68 0.84 0.00
Percent early habituation of
pulse-alone trials (between ﬁrst and second blocks)c
18.1% (5.9) 27.9% (4.3) 28.8% (7.2) 25.8% (3.1) 1.86 1/68 0.18 0.03
Percent total habituation of pulse-alone
trials (between ﬁrst and sixth blocks)c
29.3% (6.9) 42.9% (5.1) 48.6% (7.7) 40.8% (3.7) 3.01 1/68 0.09 0.05
Habituation of pulse-alone trials across
six blocks (linear gradient coeﬃcient b)c
x17.8 (5.9) x16.8 (2.6) x15.2 (1.9) x16.7 (2.2) 0.07 1/68 0.79 0.00
PANSS, Positive and Negative Syndrome Scale ; SOA, stimulus onset asynchrony.
Means are given with standard error of means (S.E.M.) in parentheses. Gender and smoking status are expressed in frequency data.
a Fisher’s exact test on violation of the Hardy–Weinberg equilibrium.
b Unmedicated patients received the value zero.
c Statistically comparing Asn/Asn vs. Ile carriers.
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demonstrates increased agonist potency by a factor
of 10. The higher frequencies of the low-functioning
Asn107 variant in schizophrenia patients compared to
healthy control subjects therefore suggest a genetically
driven deﬁciency in the NPS system in schizophrenia.
The association with schizophrenia reported here is in
contrast to Okamura et al. (2007) who did not ﬁnd any
association for NPSR1 genotype and schizophrenia.
However, the study conducted by Okamura et al.
included only 221 schizophrenia patients and 245
healthy control subjects of whom the male control
subjects were not in Hardy–Weinberg equilibrium. In
contrast our sample consisted of nearly 1500 subjects
resulting in a 3-fold larger sample. This suggests that
Okamura and colleagues might not have had suﬃcient
statistical power to detect the association of NPSR1
genotype with schizophrenia reported here. While our
study suggests a role of the Asn107 variant in schizo-
phrenia, two independent studies conﬁrmed higher
frequencies of the Ile107 variant in patients with panic
disorder (Domschke et al. 2010; Okamura et al. 2007).
Although the latter association was somewhat unex-
pected with regard to ﬁndings from rodent models
demonstrating strong anxiolytic eﬀects of NPS,
Domschke and colleagues suggest that the NPSR1-
related risk for panic disorder might be conferred by
an arousal-promoting eﬀect of the Ile107 variant. The
disease-speciﬁc pattern of the NPSR1 genotype as-
sociation with schizophrenia and panic disorder sug-
gests that NPS may exert a diﬀerential eﬀect within the
development of these two disorders.
Meta-analytical studies on neuropsychological func-
tions in schizophrenia patients document large im-
pairments of up to 1.5 S.D. units in verbal memory
(Aleman et al. 1999; Heinrichs & Zakzanis, 1998). In
our study, the schizophrenia-associated NPSR1 vari-
ant Asn107 modulated speciﬁc verbal memory func-
tions. Homozygous carriers of this variant showed
signiﬁcantly impaired retrieval and recognition of
a word list compared to subjects with the high-
functioning Ile107 variant while memory acquisition
was comparable between the diﬀerent genotypes.
A recent experimental animal trial conducted by
Okamura et al. (2010a) directly investigated NPS ef-
fects on memory. The authors observed increased
step-trough latencies in an inhibitory avoidance para-
digm after NPS injections thus conﬁrming earlier
ﬁndings of NPS facilitating fear-related memory
(Ju¨ngling et al. 2008; Okamura et al. 2010a). Moreover,
NPS also enhanced memory and recognition of non-
aﬀective objects suggesting a more general eﬀect of
NPS on memory processing. Importantly, the mem-
ory-enhancing eﬀect of NPS was only seen when the
injections were administered before the test phase
while injections before the training phase showed no
eﬀect. Based on this ﬁnding, a speciﬁc eﬀect of NPS on
memory consolidation with unaﬀected acquisition
was derived (Okamura et al. 2010a). Verbal memory
tested in human subjects, as employed in the present
study, and long-term object recognition tested in
rodents, as investigated in the Okamura et al. study,
are not directly comparable. However, it is interesting
that both studies suggest a speciﬁc eﬀect of NPS
availability on memory consolidation.
The exact pharmacological properties of NPS are
not yet fully understood. Examinations of the beha-
vioural phenotype of NPSR1 knock-out mice have
yielded inconsistent ﬁndings with regard to anxiety.
While Duangdao et al. (2009) found increased anxiety
behaviour in NPSR knock-out mice in the open ﬁeld,
the elevated maze, and the light-dark box compared to
wild-type animals, no eﬀect on startle response or PPI
was evident. Fendt et al. (2011) also reported NPSR
knock-out mice to be more anxious in the elevated
plus maze but showing a signiﬁcantly decreased
acoustic startle amplitude compared to their wild-type
littermates. However, injections of NPS reliably in-
duce an anxiolytic-like eﬀect in animals (Leonard et al.
2008; Rizzi et al. 2008; Xu et al. 2004). For instance
Leonard et al. (2008) showed comparable behavioural
eﬀects of NPS and the benzodiazepines alprazolam
and chlordiazepoxide in mice using diﬀerent tasks
thought to measure anxiety. These authors concluded
that NPS may be a novel therapeutic target for the
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Fig. 2. Signiﬁcantly reduced startle amplitude in
schizophrenia patients carrying the NPSR1 Ile107 variant.
Ile, Carriers of the Ile variant (Asn/Ile or Ile/Ile). Mean startle
amplitudes of pulse-alone (PA) trials are given and bars
indicate standard error of the mean (S.E.M.). t tests were
performed for statistical comparisons.
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treatment of anxiety disorders. Fendt et al. (2010) also
investigated the eﬀect of NPS on mice in a fear-
potentiated acoustic startle paradigm. Usually, in this
task the application of an additional electric shock
leads to a considerable increase of the startle am-
plitude. However, in the study conducted by Fendt
et al. (2010) this eﬀect could be successfully blocked by
injection of 1 nmol NPS in the amygdala.
Recently, Okamura et al. (2010b) also provided evi-
dence for a potential antipsychotic eﬀect of NPS. They
tested a pharmacological model of psychosis in mice
using MK-801, an NMDA antagonist, which elicits
strong impairments in sensorimotor gating as in-
dicated by disrupted PPI. Typically this eﬀect can
be blocked by atypical antipsychotic agents such as
clozapine (Geyer & Ellenbroek, 2003). Pre-treatment
with NPS essentially abrogated the MK-801 eﬀect
on PPI (Okamura et al. 2010b). In the present study,
analyses of acoustic startle responses yielded mixed
results. On the one hand, we did not observe any eﬀect
of NPSR1 genotype on PPI, while on the other hand,
startle reactivity was decreased in carriers of the high-
functioning Ile107 variant in our study, which conﬁrms
earlier ﬁndings of an anxiolytic eﬀect of NPS on startle
reactivity and other anxiety-related phenotypes (Fendt
et al. 2010; Ju¨ngling et al. 2008; Leonard et al. 2008;
Reinscheid et al. 2005a ; Rizzi et al. 2008; Xu et al. 2004).
Thus, carriers of the Ile107 variant determining a gain of
NPS functionality may exhibit lowered arousal, which
subsequently leads to signiﬁcantly reduced startle
reﬂexes. Surprisingly, the Asn107 variant with higher
prevalence in schizophrenia patients was associated
with normal startle amplitudes, although we and
others have shown that schizophrenia patients display
lowered startle reactivity, as was additionally con-
ﬁrmed in comparison to a healthy control group in the
present study (Braﬀ et al. 2001; Hammer et al. 2011;
Meincke et al. 2004; Moriwaki et al. 2009; Quednow
et al. 2006b, 2008). Thus, the risk allele for schizo-
phrenia appears to be protective against psychosis-
related hyporeactivity regarding the acoustic startle
response. Consequently, the NPSR1 Ile107 variant
might interact with another gene to cause both low-
ered startle response and forms of schizophrenia in
which NPSR1 plays a less signiﬁcant role. Moreover,
the Ile107 variant has been shown to be associated with
panic disorder (Domschke et al. 2010; Okamura et al.
2007), in which higher autonomic arousal is evident.
However, whether patients with panic disorder also
show an elevated startle response in general is not
clear so far. Many studies failed to demonstrate in-
creased startle responses to acoustic stimuli in panic
disorder under neutral conditions, in which no fearful
stimuli were presented and no fearful imagery was
demanded (Amrhein et al. 2005; Favaron et al. 2010;
Grillon et al. 1994; McTeague et al. 2011). Thus, our
results are not necessarily in contrast to previous
literature on the psychophysiology of panic disorder.
Unfortunately, we do not have genotype data from
healthy controls and were therefore unable to test for
a possible startle and anxiety-modulating eﬀect of
the NPSR1 Asn107Ile polymorphism in psychiatrically
unaﬀected subjects.
In conclusion, the schizophrenia patients in
our study had a reduced prevalence of the high-
functioning NPSR1 Ile107 variant probably leading to a
less activeNPS system and contributing to thememory
impairments typically observed in these patients. An
interaction of theNPSR1 gene and other schizophrenia
susceptibility genes may contribute to a diﬀerentially
modulated startle response. We suggest that adjuvant
administration of NPS might show antipsychotic ef-
fects in patients with schizophrenia and might help to
improve cognitive disruptions like impaired memory
functions in schizophrenia.
Acknowledgements
This study was part of the German Research Network
on Schizophrenia and was funded by the German
Federal Ministry for Education and Research (BMBF)
(grants 01GI0501, 01GI0232, 01GI0234, 01GV0907,
and NGFN+MooDs PNM-01GS08146-3), the German
Research Foundation (DFG) (grants Wa 731/6 and Wa
731/4), and by the 7th framework programme of the
European Union (ADAMS project, HEALTH-F4-2009-
242257). Dr Quednow is supported by the Swiss
National Science Foundation (grant no. PP00P1_
123516). We thank V. Guttenthaler and A. Petruschke
for expert technical assistance. The authors thank all
clinicians, psychiatrists, psychologists, and study
nurses involved in the study.
Statement of Interest
None.
References
Aleman A, Hijman R, de Haan EH, Kahn RS (1999).
Memory impairment in schizophrenia : a meta-analysis.
American Journal of Psychiatry 156, 1358–1366.
Amrhein C, Pauli P, Dengler W, Wiedemann G (2005).
Covariation bias and its physiological correlates in panic
disorder patients. Journal of Anxiety Disorders 19, 177–191.
APA (1994). Diagnostic and Statistical Manual of Mental
Disorders. Washington, DC: American Psychiatric
Association.
Neuropeptide S in schizophrenia 9
Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have
similar pharmacological characteristics? A review of the
evidence. Neuropsychopharmacology 18, 63–101.
Arranz MJ, de Leon J (2007). Pharmacogenetics and
pharmacogenomics of schizophrenia : a review of last
decade of research. Molecular Psychiatry 12, 707–747.
Becker T, Knapp M (2004). Maximum-likelihood estimation
of haplotype frequencies in nuclear families. Genetic
Epidemiology 27, 21–32.
Bernier V, Stocco R, Bogusky MJ, Joyce JG, et al. (2006).
Structure-function relationships in the neuropeptide
S receptor : molecular consequences of the
asthma-associated mutation N107I. Journal of Biological
Chemistry 281, 24704–24712.
Braﬀ DL, Geyer MA, Light GA, Sprock J, et al. (2001).
Impact of prepulse characteristics on the detection of
sensorimotor gating deﬁcits in schizophrenia.
Schizophrenia Research 49, 171–178.
Braﬀ DL, Grillon C, Geyer MA (1992). Gating and
habituation of the startle reﬂex in schizophrenic patients.
Archives of General Psychiatry 49, 206–215.
Carlsson A (1978). Antipsychotic drugs, neurotransmitters,
and schizophrenia. American Journal of Psychiatry 135,
165–173.
Domschke K, Reif A, Weber H, Richter J, et al. (2010).
Neuropeptide S receptor gene – converging evidence for
a role in panic disorder. Molecular Psychiatry 16, 938–948.
Duangdao DM, Clark SD, Okamura N, Reinscheid RK
(2009). Behavioral phenotyping of neuropeptide S receptor
knockout mice. Behavioural Brain Research 205, 1–9.
Favaron E, Bellodi L, Biﬃ S, Vanni G, et al. (2010).
Acoustic startle response in panic disorder. Psychiatry
Research 176, 254–256.
Fendt M, Buchi M, Burki H, Imobersteg S, et al. (2011).
Neuropeptide S receptor deﬁciency modulates
spontaneous locomotor activity and the acoustic startle
response. Behavioural Brain Research 217, 1–9.
Fendt M, Imobersteg S, Burki H, McAllister KH, et al.
(2010). Intra-amygdala injections of neuropeptide S block
fear-potentiated startle. Neuroscience Letters 474, 154–157.
Geﬀen G, Moar KJ, O’Hanlon AP, Clark CR, et al. (1990).
Performance measures of 16- to 86-year-old males and
females on the auditory verbal learning test. Clinical
Neuropsychologist 4, 45–63.
Geyer MA, Braﬀ DL (1982). Habituation of the Blink reﬂex
in normals and schizophrenic patients. Psychophysiology
19, 1–6.
Geyer MA, Ellenbroek B (2003). Animal behavior models
of the mechanisms underlying antipsychotic atypicality.
Progress in Neuro-Psychopharmacology and Biological
Psychiatry 27, 1071–1079.
Grillon C, Ameli R, Goddard A, Woods SW, et al. (1994).
Baseline and fear-potentiated startle in panic disorder
patients. Biological Psychiatry 35, 431–439.
Hammer TB, Oranje B, Fagerlund B, Bro H, et al. (2011).
Stability of prepulse inhibition and habituation of the
startle reﬂex in schizophrenia : a 6-year follow-up study of
initially antipsychotic-naive, ﬁrst-episode schizophrenia
patients. International Journal of Neuropsychopharmacology
14, 913–925.
Heinrichs RW, Zakzanis KK (1998). Neurocognitive deﬁcit
in schizophrenia : a quantitative review of the evidence.
Neuropsychology 12, 426–445.
Helmstaedter C, Lendt M, Lux S (2001). VLMT – Verbaler
Lern- und Merkfa¨higkeitstest Manual. Go¨ttingen : Beltz.
Howes OD, Kapur S (2009). The dopamine hypothesis of
schizophrenia : version III – the ﬁnal common pathway.
Schizophrenia Bulletin 35, 549–562.
Ju¨ngling K, Seidenbecher T, Sosulina L, Lesting J, et al.
(2008). Neuropeptide S-mediated control of fear expression
and extinction : role of intercalated GABAergic neurons in
the amygdala. Neuron 59, 298–310.
Kay SR, Opler LA, Fiszbein A (1992). Positive and Negative
Syndrome Scale (PANSS). Manual. North Tonawanda, NY:
Multi-Health Systems Inc.
Kumari V, Gray JA (1999). Smoking withdrawal, nicotine
dependence and prepulse inhibition of the acoustic startle
reﬂex. Psychopharmacology (Berlin) 141, 11–15.
Lehrl S, Merz J, Burkhard G, Fischer S (1999).Mehrfachwahl-
Wortschatz-Intelligenztest. Go¨ttingen : Hogrefe.
Leonard SK, Dwyer JM, Sukoﬀ Rizzo SJ, Platt B, et al.
(2008). Pharmacology of neuropeptide S in mice :
therapeutic relevance to anxiety disorders.
Psychopharmacology (Berlin) 197, 601–611.
McTeague LM, Lang PJ, Laplante MC, Bradley MM (2011).
Aversive imagery in panic disorder : agoraphobia
severity, comorbidity, and defensive physiology. Biological
Psychiatry 70, 415–424.
Meincke U, Light GA, Geyer MA, Braﬀ DL, et al. (2004).
Sensitization and habituation of the acoustic startle reﬂex
in patients with schizophrenia. Psychiatry Research 126,
51–61.
Moriwaki M, Kishi T, Takahashi H, Hashimoto R, et al.
(2009). Prepulse inhibition of the startle response with
chronic schizophrenia : a replication study. Neuroscience
Research 65, 259–262.
Okamura N, Garau C, Duangdao DM, Clark SD, et al.
(2010a). Neuropeptide S enhances memory during the
consolidation phase and interacts with noradrenergic
systems in the brain. Neuropsychopharmacology 36, 744–752.
Okamura N, Hashimoto K, Iyo M, Shimizu E, et al. (2007).
Gender-speciﬁc association of a functional coding
polymorphism in the Neuropeptide S receptor gene with
panic disorder but not with schizophrenia or
attention-deﬁcit/hyperactivity disorder. Progress in
Neuro-Psychopharmacology and Biological Psychiatry 31,
1444–1448.
OkamuraN, Reinscheid RK, Ohgake S, IyoM, et al. (2010b).
Neuropeptide S attenuates neuropathological,
neurochemical and behavioral changes induced by the
NMDA receptor antagonist MK-801. Neuropharmacology
58, 166–172.
Quednow BB, Frommann I, Berning J, Kuhn KU, et al.
(2008). Impaired sensorimotor gating of the acoustic startle
response in the prodrome of schizophrenia. Biological
Psychiatry 64, 766–773.
10 L. Lennertz et al.
Quednow BB, Kuhn KU, Beckmann K, Westheide J, et al.
(2006a). Attenuation of the prepulse inhibition of the
acoustic startle response within and between sessions.
Biological Psychology 71, 256–263.
Quednow BB, Wagner M, Westheide J, Beckmann K, et al.
(2006b). Sensorimotor gating and habituation of the
startle response in schizophrenic patients randomly
treated with amisulpride or olanzapine. Biological
Psychiatry 59, 536–545.
Reinscheid RK (2008). Neuropeptide S : anatomy,
pharmacology, genetics and physiological functions.
Results and Problems in Cell Diﬀerentiation 46, 145–158.
Reinscheid RK, Xu YL (2005a). Neuropeptide S and its
receptor : a newly deorphanized G protein-coupled
receptor system. Neuroscientist 11, 532–538.
Reinscheid RK, Xu YL (2005b). Neuropeptide S as a novel
arousal promoting peptide transmitter. FEBS Journal 272,
5689–5693.
Reinscheid RK, Xu YL, Civelli O (2005a). Neuropeptide S :
a new player in the modulation of arousal and anxiety.
Molecular Interventions 5, 42–46.
Reinscheid RK, Xu YL, Okamura N, Zeng J, et al. (2005b).
Pharmacological characterization of human and murine
neuropeptide S receptor variants. Journal of Pharmacology
and Experimental Therpeutics 315, 1338–1345.
Rizzi A, Vergura R, Marzola G, Ruzza C, et al. (2008).
Neuropeptide S is a stimulatory anxiolytic agent : a
behavioural study in mice. British Journal of Pharmacology
154, 471–479.
WHO (1992). International Classiﬁcation of Disease, Tenth
Revision. Geneva, Switzerland: World Health
Organisation.
Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD,
et al. (2004). Neuropeptide S : a neuropeptide
promoting arousal and anxiolytic-like eﬀects. Neuron
43, 487–497.
Neuropeptide S in schizophrenia 11
